WEREWOLF THERAPEUTICS INC (HOWL) Stock Price & Overview

NASDAQ:HOWLUS95075A1079

Current stock price

1.03 USD
-0.01 (-0.96%)
Last:

The current stock price of HOWL is 1.03 USD. Today HOWL is down by -0.96%. In the past month the price increased by 64.58%. In the past year, price increased by 46.48%.

HOWL Key Statistics

52-Week Range0.5301 - 2.38
Current HOWL stock price positioned within its 52-week range.
1-Month Range0.6202 - 1.14
Current HOWL stock price positioned within its 1-month range.
Market Cap
49.996M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.33
Dividend Yield
N/A

HOWL Stock Performance

Today
-0.96%
1 Week
+33.20%
1 Month
+64.58%
3 Months
+72.33%
Longer-term
6 Months -36.20%
1 Year +46.48%
2 Years -83.33%
3 Years -56.12%
5 Years N/A
10 Years N/A

HOWL Stock Chart

WEREWOLF THERAPEUTICS INC / HOWL Daily stock chart

HOWL Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to HOWL. When comparing the yearly performance of all stocks, HOWL is one of the better performing stocks in the market, outperforming 92.33% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HOWL Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to HOWL. HOWL may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HOWL Earnings

Next Earnings DateMay 1, 2026
Last Earnings DateMar 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.17
Revenue Reported
EPS Surprise 51.69%
Revenue Surprise %

HOWL Forecast & Estimates

11 analysts have analysed HOWL and the average price target is 6.38 USD. This implies a price increase of 518.93% is expected in the next year compared to the current price of 1.03.


Analysts
Analysts85.45
Price Target6.38 (519.42%)
EPS Next Y-12.8%
Revenue Next YearN/A

HOWL Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

HOWL Financial Highlights

Over the last trailing twelve months HOWL reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 18.4% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-72.84M
Industry RankSector Rank
PM (TTM) N/A
ROA -91.48%
ROE -245.97%
Debt/Equity 0.73
Chartmill High Growth Momentum
EPS Q2Q%63.04%
Sales Q2Q%N/A
EPS 1Y (TTM)18.4%
Revenue 1Y (TTM)N/A

HOWL Ownership

Ownership
Inst Owners41.15%
Shares48.54M
Float45.81M
Ins Owners1.39%
Short Float %3.06%
Short Ratio3.24

About HOWL

Company Profile

HOWL logo image Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Company Info

IPO: 2021-04-30

WEREWOLF THERAPEUTICS INC

200 Talcott Avenue, 2nd Floor

Watertown MASSACHUSETTS 02138 US

CEO: Daniel J. Hicklin

Employees: 46

HOWL Company Website

HOWL Investor Relations

Phone: 16179520555

WEREWOLF THERAPEUTICS INC / HOWL FAQ

What does WEREWOLF THERAPEUTICS INC do?

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.


What is the stock price of WEREWOLF THERAPEUTICS INC today?

The current stock price of HOWL is 1.03 USD. The price decreased by -0.96% in the last trading session.


Does HOWL stock pay dividends?

HOWL does not pay a dividend.


What is the ChartMill technical and fundamental rating of HOWL stock?

HOWL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the GICS sector and industry of HOWL stock?

WEREWOLF THERAPEUTICS INC (HOWL) operates in the Health Care sector and the Biotechnology industry.


How is the valuation of WEREWOLF THERAPEUTICS INC (HOWL) based on its PE ratio?

WEREWOLF THERAPEUTICS INC (HOWL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.33).


Who owns WEREWOLF THERAPEUTICS INC?

You can find the ownership structure of WEREWOLF THERAPEUTICS INC (HOWL) on the Ownership tab.